Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine
Open Access
- 17 January 2006
- journal article
- review article
- Published by Springer Nature in The Pharmacogenomics Journal
- Vol. 6 (3) , 162-165
- https://doi.org/10.1038/sj.tpj.6500361
Abstract
Pharmacogenetics arose with studies of single genes, which had major effects on the action of particular drugs. It turned into pharmacogenomics through realization that the controls of most drug responses are multifactorial. Then, variable gene expression posed new problems, for example what do drugs do to genes, or how useful is any genetic pretesting of a person? A common disease may be caused by different groups of genes in different people, who therefore require different drugs for treatment. Personlized medicine is currently represented by a physician's attention to a patients age, sex, or ethnic backround, that is groups showing smaller genetic variation than is typical for general humanity. Occasionally, there is also the use of single-gene pretesting of a patient before drug administration. Over time, improvements in multigenic testing promise to increase the role of personalized medicine. However, the many pharmacogenomic complexities, and particularly time-dependent changes of gene expression, will never allow personalized medicine to become an error-free entity.Keywords
This publication has 39 references indexed in Scilit:
- Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseasesEuropean Heart Journal, 2005
- Concepts in nuclear architectureBioEssays, 2005
- Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance doseThe Pharmacogenomics Journal, 2005
- Gene expression induced by drugs of abuseCurrent Opinion in Pharmacology, 2005
- Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityThe Pharmacogenomics Journal, 2004
- Glucose 6-Phosphate Dehydrogenase (G6PD) DeficiencyPublished by Elsevier ,2001
- Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and FrailtyAnnual Review of Medicine, 2000
- Comment on “study of glucose‐6‐phosphate dehydrogenase: History and molecular biology,” by Ernest Beutler, Am J Hematol 42:53–58, 1993American Journal of Hematology, 1993
- Ethnic Differences in Drug MetabolismClinical Pharmacokinetics, 1982
- FAMILIAL INCIDENCE OF LOW PSEUDOCHOLINESTERASE LEVELThe Lancet, 1956